Show simple item record

dc.contributor.authorRimner, A.
dc.contributor.authorLai, W. V.
dc.contributor.authorCalifano, R.
dc.contributor.authorJabbour, S. K.
dc.contributor.authorRudin, C. M.
dc.contributor.authorFaivre-Finn, Corinne
dc.contributor.authorCho, B. C.
dc.contributor.authorKato, T.
dc.contributor.authorYu, J.
dc.contributor.authorChafin, W.
dc.contributor.authorYu, L.
dc.contributor.authorZhao, B.
dc.contributor.authorByers, L.
dc.date.accessioned2022-06-22T07:18:34Z
dc.date.available2022-06-22T07:18:34Z
dc.date.issued2022en
dc.identifier.citationRimner A, Lai WCV, Califano R, Jabbour SK, Rudin CM, Faivre-Finn C, et al. Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer. Vol. 23, Clinical Lung Cancer. Elsevier BV; 2022. p. e325–9.en
dc.identifier.pmid35613997en
dc.identifier.doi10.1016/j.cllc.2022.04.005en
dc.identifier.urihttp://hdl.handle.net/10541/625329
dc.description.abstractBackground: The current standard of care for patients with newly diagnosed limited-stage small-cell lung cancer (SCLC) is concurrent chemoradiotherapy (CCRT). The prognosis remains poor due to the aggressiveness and high risk of progression or relapse of SCLC even if an initial response is achieved. Therefore, there is an urgent unmet clinical need in this population. The multicenter, phase 3, randomized, placebo-controlled, double-blind KEYLYNK-013 study evaluates the addition of pembrolizumab to CCRT followed by pembrolizumab with or without olaparib in participants with previously untreated limited-stage SCLC. (ClinicalTrials.gov: NCT04624204). Methods: Eligible participants aged ≥18 years with newly diagnosed, pathologically confirmed, limited-stage (ie, stage I-III) SCLC will be randomized 1:1:1 to CCRT (ie, etoposide plus carboplatin or cisplatin for 4 cycles and standard thoracic radiotherapy) plus pembrolizumab (Groups A and B) or CCRT plus placebo (Group C). In the absence of disease progression, participants will receive pembrolizumab plus placebo (Group A), pembrolizumab plus olaparib (Group B), or placebo (Group C). Dual primary endpoints are progression-free survival per RECIST version 1.1 by blinded independent central review and overall survival. Results: Enrollment began in December 2020 and is ongoing at approximately 150 sites. Conclusions: KEYLYNK-013 will provide valuable information on the efficacy and safety of pembrolizumab plus CCRT and pembrolizumab with or without olaparib post CCRT in participants with limited-stage SCLC.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.cllc.2022.04.005en
dc.titleRationale and design of the phase 3 KEYLYNK-013 study of pembrolizumab with concurrent chemoradiotherapy followed by pembrolizumab with or without olaparib for limited-stage small-cell lung canceren
dc.typeArticleen
dc.contributor.departmentMemorial Sloan Kettering Cancer Center, New York, NYen
dc.identifier.journalClinical Lung Canceren
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record